Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report) was the recipient of a significant increase in short interest in February. As of February 28th, there was short interest totalling 119,700 shares, an increase of 93.4% from the February 13th total of 61,900 shares. Based on an average daily volume of 4,130,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 6.5% of the company’s stock are sold short.
Institutional Trading of Cyclerion Therapeutics
An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Renaissance Technologies LLC acquired a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,611 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned about 0.39% of Cyclerion Therapeutics as of its most recent SEC filing. 75.62% of the stock is currently owned by hedge funds and other institutional investors.
Cyclerion Therapeutics Price Performance
CYCN stock traded up $0.06 during mid-day trading on Friday, reaching $2.53. The company had a trading volume of 7,764 shares, compared to its average volume of 2,412,826. The stock has a 50 day simple moving average of $3.05 and a two-hundred day simple moving average of $2.90. The company has a market capitalization of $6.86 million, a price-to-earnings ratio of -2.07 and a beta of 2.09. Cyclerion Therapeutics has a 52 week low of $1.27 and a 52 week high of $9.47.
About Cyclerion Therapeutics
Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.
Featured Stories
- Five stocks we like better than Cyclerion Therapeutics
- The Risks of Owning Bonds
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Upcoming IPO Stock Lockup Period, Explained
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What Are Dividend Champions? How to Invest in the Champions
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.